Real-world database analysis of the characteristics and treatment patterns of patients with endometrial cancer in Japan

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021. DOI:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Nagase S, Ohta T, Takahashi F, 2017 Committee on Gynecologic Oncology of the Japan Society of Obstetrics and Gynecology, et al. Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology: Annual patients report for 2015 and annual treatment report for 2010. J Obstet Gynaecol Res. 2019;45:289–298.
   PubMed Web of Science ®Google Scholar
• Lee NK, Cheung MK, Shin JY, et al. Prognostic factors for uterine cancer in reproductive-aged women. Obstet Gynecol. 2007;109:655–662.
   PubMed Web of Science ®Google Scholar
• Esposito K, Chiodini P, Capuano A, et al. Metabolic syndrome and endometrial cancer: a meta-analysis. Endocrine. 2014;45:28–36.
   PubMed Web of Science ®Google Scholar
• Raglan O, Kalliala I, Markozannes G, et al. Risk factors for endometrial cancer: an umbrella review of the literature. Int J Cancer. 2019;145:1719–1730.
   PubMed Web of Science ®Google Scholar
• Bradford LS, Rauh-Hain JA, Schorge J, et al. Advances in the management of recurrent endometrial cancer. Am J Clin Oncol. 2015;38:206–212.
   PubMed Web of Science ®Google Scholar
• Lu KH, Broaddus RR. Endometrial cancer. N Engl J Med. 2020;383:2053–2064.
   PubMed Web of Science ®Google Scholar
• Morice P, Leary A, Creutzberg C, et al. Endometrial cancer. Lancet. 2016;387:1094–1108. 12
   PubMed Web of Science ®Google Scholar
• Oaknin A, León-Castillo A, Lorusso D. Progress in the management of endometrial cancer (subtypes, immunotherapy, alterations in PIK3CA pathway): data and perspectives. Curr Opin Oncol. 2020;32:471–480.
   PubMed Web of Science ®Google Scholar
• Neri M, Peiretti M, Melis GB, et al. Systemic therapy for the treatment of endometrial cancer. Expert Opin Pharmacother. 2019;20:2019–2032.
   PubMed Web of Science ®Google Scholar
• Wright JD, Barrena Medel NI, Sehouli J, et al. Contemporary management of endometrial cancer. Lancet. 2012;379:1352–1360.
   PubMed Web of Science ®Google Scholar
• Bendifallah S, Ilenko A, Daraï E. High risk endometrial cancer: clues towards a revision of the therapeutic paradigm. J Gynecol Obstet Hum Reprod. 2019;48:863–871.
   PubMed Web of Science ®Google Scholar
• Palisoul M, Mutch DG. The clinical management of inoperable endometrial carcinoma. Expert Rev Anticancer Ther. 2016;16:515–521.
   PubMed Web of Science ®Google Scholar
• Ueda SM, Kapp DS, Cheung MK, et al. Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. Am J Obstet Gynecol. 2008;198:218.e1–e6.
   Web of Science ®Google Scholar
• Akada K, Koyama N, Taniguchi S, et al. Database analysis of patients with hepatocellular carcinoma and treatment flow in early and advanced stages. Pharmacol Res Perspect. 2019;7:e00486.
   PubMed Web of Science ®Google Scholar
• Nakashima M, Takeuchi M, Kawakami K. Effectiveness and safety of regorafenib vs. trifluridine/tipiracil in unresectable colorectal cancer: a retrospective cohort study. Clin Colorectal Cancer. 2020;19:e208–e225.
   PubMed Web of Science ®Google Scholar
• Fotopoulou C, Kraetschell R, Dowdy S, et al. Surgical and systemic management of endometrial cancer: an international survey. Arch Gynecol Obstet. 2015;291:897–905.
   PubMed Web of Science ®Google Scholar
• Lee JY, Kim JW, Lee TS, et al. Difference in practice patterns in the management of endometrial cancer: a survey of the members of 4 East Asian Gynecologic Oncology Groups. Int J Gynecol Cancer. 2017;27:1888–1894.
   PubMed Web of Science ®Google Scholar
• Gómez-Raposo C, Merino Salvador M, Aguayo Zamora C, et al. Adjuvant chemotherapy in endometrial cancer. Cancer Chemother Pharmacol. 2020;85:477–486.
   PubMed Web of Science ®Google Scholar
• Miller DS, Filiaci VL, Mannel RS, et al. Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase III trial (NRG Oncology/GOG0209). J Clin Oncol. 2020;38:3841–3850.
   PubMed Web of Science ®Google Scholar
• Nomura H, Aoki D, Michimae H, Japanese Gynecologic Oncology Group, et al. Effect of taxane plus platinum regimens vs doxorubicin plus cisplatin as adjuvant chemotherapy for endometrial cancer at a high risk of progression: a randomized clinical trial. JAMA Oncol. 2019;5:833–840.
   PubMed Web of Science ®Google Scholar
• Nomura H, Aoki D, Susumu N, et al. Analysis of the relapse patterns and risk factors of endometrial cancer following postoperative adjuvant chemotherapy in a phase III randomized clinical trial. Gynecol Oncol. 2019;155:413–419.
   PubMed Web of Science ®Google Scholar
• Odagiri T, Watari H, Hosaka M, et al. Multivariate survival analysis of the patients with recurrent endometrial cancer. J Gynecol Oncol. 2011;22:3–8.
   PubMed Web of Science ®Google Scholar
• Iwase H, Furukawa S, Hirasawa T, et al. The clinical features of recurrent endometrial cancer in japan: chemotherapy instead of radiotherapy as postoperative adjuvant treatment. Int J Gynecol Cancer. 2018;28:1616–1623.
   PubMed Web of Science ®Google Scholar
• Ueda Y, Miyake T, Egawa-Takata T, et al. Second-line chemotherapy for advanced or recurrent endometrial carcinoma previously treated with paclitaxel and carboplatin, with or without epirubicin. Cancer Chemother Pharmacol. 2011;67:829–835.
   PubMed Web of Science ®Google Scholar
• Nagao S, Nishio S, Michimae H, et al. Applicability of the concept of “platinum sensitivity” to recurrent endometrial cancer: the SGSG-012/GOTIC-004/Intergroup study. Gynecol Oncol. 2013;131:567–573.
   PubMed Web of Science ®Google Scholar
• Nagao S, Nishio S, Okada S, et al. What is an appropriate second-line regimen for recurrent endometrial cancer? Ancillary analysis of the SGSG012/GOTIC004/Intergroup study. Cancer Chemother Pharmacol. 2015;76:335–342.
   PubMed Web of Science ®Google Scholar
• Bergamini A, Bocciolone L, Fodor A, et al. Management of recurrent ovarian cancer: when platinum-based regimens are not a therapeutic option. Int J Gynecol Cancer. 2019;29:1431–1436.
   PubMed Web of Science ®Google Scholar
• Connor EV, Rose PG. Management strategies for recurrent endometrial cancer. Expert Rev Anticancer Ther. 2018;18:873–885.
   PubMed Web of Science ®Google Scholar
• Rubinstein M, Halpenny D, Makker V, et al. Retreatment with carboplatin and paclitaxel for recurrent endometrial cancer: A retrospective study of the Memorial Sloan Kettering Cancer Center experience. Gynecol Oncol Rep. 2019;28:120–123.
   PubMed Web of Science ®Google Scholar
• Fleming GF. Second-line therapy for endometrial cancer: the need for better options. J Clin Oncol. 2015;33:3535–3540.
   PubMed Web of Science ®Google Scholar
• Bestvina CM, Fleming GF. Chemotherapy for endometrial cancer in adjuvant and advanced disease settings. Oncologist. 2016;21:1250–1259.
   PubMed Web of Science ®Google Scholar
• McMeekin S, Dizon D, Barter J, et al. Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer. Gynecol Oncol. 2015;138:18–23.
   PubMed Web of Science ®Google Scholar
• Yoshida H, Imai Y, Fujiwara K. Combination chemotherapy with docetaxel and carboplatin for elderly patients with endometrial cancer. Mol Clin Oncol. 2016;4:783–788.
   PubMed Web of Science ®Google Scholar
• Ouldamer L, Bendifallah S, Body G, et al. Groupe de Recherche FRANCOGYN. Change in hazard rates of recurrence over time following diagnosis of endometrial cancer: An age stratified multicentre study from the FRANCOGYN group. Eur J Surg Oncol. 2018;44:1914–1920.
   PubMed Web of Science ®Google Scholar
• Yoshida H, Shintani D, Kawashima N, et al. Predicting toxicity of platinum and taxane-based chemotherapy in older patients with gynecologic cancer. J Buon. 2020;25:736–742.
   PubMed Web of Science ®Google Scholar
• Yunokawa M, Sasada S, Takehara Y, et al. Real-world data on initial treatment strategies for older adult patients with endometrial cancer in Japan. Cancer Chemother Pharmacol. 2019;84:1051–1058.
   PubMed Web of Science ®Google Scholar
• Hay CM, Donovan HS, Campbell GB, et al. Chemotherapy in older adult gynecologic oncology patients: Can a phenotypic frailty score predict tolerance? Gynecol Oncol. 2019;152:304–309.
   PubMed Web of Science ®Google Scholar